<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04512586</url>
  </required_header>
  <id_info>
    <org_study_id>His_PAAF_study</org_study_id>
    <nct_id>NCT04512586</nct_id>
  </id_info>
  <brief_title>His-pacing and AV-node Ablation vs. Pulmonary Vein Isolation for Atrial Fibrillation</brief_title>
  <acronym>His-PAAF</acronym>
  <official_title>Physiological Pacemaker Treatment in Combination With AV Node Ablation Compared With Pulmonary Vein Isolation for Patients With Symptomatic Atrial Fibrillation - a Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Region Skane</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective To investigate if conduction system pacing (i.e. atrioventricular node ablation +&#xD;
      His bundle pacing) is as good as (or better than) atrial fibrillation ablation with pulmonary&#xD;
      vein isolation for older patients (70-85yrs) with symptomatic atrial fibrillation and at&#xD;
      least moderately dilated left atrium.&#xD;
&#xD;
      Patient population:&#xD;
&#xD;
      90 patients aged 70-85 years with atrial fibrillation, referred to either AV node ablation or&#xD;
      pulmonary vein isolation.&#xD;
&#xD;
      Primary endpoint:&#xD;
&#xD;
      Improvement in health-related quality of life as measured by the physical component summary&#xD;
      (PCS) of the well-validated SF-36 form, at one year after AV node ablation + His bundle&#xD;
      pacing or AF ablation.&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
      Physical performance measured by 6-minute walk test, biochemical markers of heart failure&#xD;
      (NT-ProBNP), frequency of complications, left ventricular systolic and diastolic function,&#xD;
      and left atrial size evaluated after 12 months. Arrhythmia specific symptoms and anxiety will&#xD;
      be measured with the ASTA and HADS questionnaires. Arrhythmia symptom correlation between&#xD;
      subjective and objective findings. After three years, clinical endpoints will be evaluated&#xD;
      regarding overall survival, and risk of heart failure hospitalization or death. The cost of&#xD;
      the treatments will be compared, and estimated cost per quality adjusted year of life will be&#xD;
      calculated, based on the EQ5D questionnaire.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients are randomized to either&#xD;
Conduction system pacing via His-pacing electrode, in combination with AV node ablation&#xD;
Pulmonary vein isolation ablation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Health related Quality of Life: questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>Improvement in the Physical Component Summary (PCS) of the SF-36 questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety endpoint: Proportion of patients with major adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of patients with major adverse events that are devicerelated or related to ablation procedure (including but not limited to exit block, infection, perforation/tamponade, pericardial effusion, lead dislodgement, TIA/stroke, oesophago-atrial fistula, groin hematoma or vascular complication, pseudoaneurysm, phrenic nerve injury).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mental Quality of Life: questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>Improvement of the &quot;mental&quot; health related quality of life, measured by the mental component summary (MCS) of the SF-36 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arrhythmia related Quality of Life: ASTA questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>Change in arrhythmia related quality of life as measured by the The Arrhythmia-Specific questionnaire in Tachycardia. The ASTA questionnaire consists of 13 items, each with a score of 0-4. A higher score denotes more symptoms associated with the arrhythmia.&#xD;
and Arrhythmia (ASTA) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and depression</measure>
    <time_frame>12 months</time_frame>
    <description>Anxiety and depression symptoms, measured by the Hospital Anxiety and Depression Scale (HADS). The scale consists of 14 questions with 0 to 3 points for each, with a higher score denoting more depression/anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ejection fraction</measure>
    <time_frame>12 months</time_frame>
    <description>Change in left ventricular systolic ejection fraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker for heart failure</measure>
    <time_frame>12 months</time_frame>
    <description>Change in NT-ProBNP level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical performance</measure>
    <time_frame>12 months</time_frame>
    <description>Change in six minute walk test distance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiography changes</measure>
    <time_frame>12 months</time_frame>
    <description>Change in QRS duration on ECG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economy</measure>
    <time_frame>12 months</time_frame>
    <description>Total atrial fibrillation and device related health care cost</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>3 years</time_frame>
    <description>Total survival and survival free of major complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for heart failure</measure>
    <time_frame>3 years</time_frame>
    <description>Risk of hospitalization for heart failure assessed by Kaplan Meier time dependent analysis using time from ablation to first hospitalization for heart failure within three years</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Left Atrial Dilatation</condition>
  <arm_group>
    <arm_group_label>His-pacing plus AV node ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A His-pacing lead in combination with a backup RV pacing lead, and a right atrial lead (if needed) will be placed using standard technique. The His-pacing lead will be Medtronic 3830, and the outer sheath will be either Medtronic C304 or C315 deflectable. A standard DDD pacemaker or CRT-P device from Medtronic will be used.&#xD;
A minimum of three weeks post-implant, the device will be interrogated and His-bundle threshold will be evaluated. A threshold of ≤2.0V@1.0ms is acceptable. If the device is well-functioning and successful His-pacing is documented, AV node ablation will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulmonary vein isolation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atrial fibrillation will be performed as a complete pulmonary vein isolation. Either Cryoballon or radio frequency ablation with irrigated tip contact force enabled catheter can be used. Endpoint is complete electrical isolation of all pulmonary veins, verified by entry- and exit block using a multipolar catheter during pacing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>His-bundle pacing and AV node ablation</intervention_name>
    <description>See study arm description.</description>
    <arm_group_label>His-pacing plus AV node ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Atrial fibrillation ablation by pulmonary vein isolation</intervention_name>
    <description>See study arm description</description>
    <arm_group_label>Pulmonary vein isolation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Indication for invasive treatment of symptomatic atrial fibrillation according to&#xD;
             current guidelines&#xD;
&#xD;
          -  LVEF &gt;35%&#xD;
&#xD;
          -  Age 70-85 years&#xD;
&#xD;
          -  Persistent atrial fibrillation, or paroxysmal atrial fibrillation with at least&#xD;
             moderate enlargement of the left atrium (≥42ml/m2)&#xD;
&#xD;
          -  Chronic and well-tolerated treatment with anticoagulants (either non-vitamin K oral&#xD;
             anticoagulant or vitamin K antagonist)&#xD;
&#xD;
          -  Willingness to participate, to understand the instructions and fill out the&#xD;
             questionnaires, and ability to sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic atrial fibrillation with &gt;1 year duration&#xD;
&#xD;
          -  BMI &gt;40kg/m2&#xD;
&#xD;
          -  Hypertrophic cardiomyopathy&#xD;
&#xD;
          -  Severe heart failure with symptoms ≥ NYHA class IIIb&#xD;
&#xD;
          -  Heart amyloidosis&#xD;
&#xD;
          -  Cardiac sarcoidosis&#xD;
&#xD;
          -  Recent (&lt;3 months) myocardial infarction&#xD;
&#xD;
          -  Significant heart valve disease (pronounced insufficiency or stenosis)&#xD;
&#xD;
          -  Pacemaker or ICD treatment ongoing, or current pacemaker indication&#xD;
&#xD;
          -  Congenital heart disease that required surgical correction&#xD;
&#xD;
          -  Comorbidity that is assessed significantly affect the patient's quality of life over&#xD;
             the next year, or 3-year survival&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rasmus Borgquist, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University, Skane University Hospital, Arrhythmia Section, Lund, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rasmus Borgquist, MD PhD</last_name>
    <phone>+4646171010</phone>
    <email>rasmus.borgquist@med.lu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cecilia Rorsman, MD</last_name>
    <email>Cecilia.Rorsman@regionhalland.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Linköping University</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ulla Walfridsson, RN PhD</last_name>
      <email>Ulla.walfridsson@regionostergotland.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stockholm Arrhythmia Center</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Varberg Hospital</name>
      <address>
        <city>Varberg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecilia Rorsman, MD</last_name>
      <email>cecilia.rorsman@med.lu.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 1, 2020</study_first_submitted>
  <study_first_submitted_qc>August 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2020</study_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Left atrial dilatation</keyword>
  <keyword>Pulmonary vein isolation</keyword>
  <keyword>AV node ablation</keyword>
  <keyword>His bundle pacing</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Age group 70 to 85 years</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Dilatation, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

